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Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is characterized by the degener-
ation of dopamine (DA) and non-DA neurons, the almost uniform presence of Lewy bodies, and motor defi-
cits. Although the majority of PD is sporadic, specific genetic defects in rare familial cases have provided
unique insights into the pathogenesis of PD. Through the creation of animal and cellular models of mutations
in LRRK2 and a-synuclein, which are linked to autosomal-dominant PD, and mutations in parkin, DJ-1, and
PINK1, which are responsible for autosomal-recessive PD, insight into the molecular mechanisms of this
disorder are leading to new ideas about the pathogenesis of PD. In this review, we discuss the animal models
for these genetic causes of PD, their limitations, and value. Moreover, we discuss future directions and poten-
tial strategies for optimization of the genetic models.Introduction
Parkinson’s disease (PD) is the most common neurodegenerative
movement disorder (Lees et al., 2009). It is chronic and relent-
lessly progressive and affects more than 1% of the population
over age 60. A distinct anatomical circuit, the nigrostriatal
pathway, is preferentially damaged in PD, which is important for
the fine modulation of motor function. Lewy body inclusions and
relative selective loss of dopamine (DA) neurons in the substantia
nigra pars compacta are the pathologic and anatomical hallmarks
of PD. However, there are some cases of genetic PD that do not
have Lewy bodies. Currently, no proven treatment can halt or
even slow the progression of this disease. Although dopamine
supplementation is currently used for PD as a means to replace
the diminished tone of dopaminergic output from substantia nigra
pars compacta, it only alleviates the symptomatic motor dysfunc-
tion, and its effectiveness declines as the disease progresses.
Therefore, it is essential to develop suitable animal models that
can be used for the screening and testingof new therapeutic strat-
egies targeting the actual pathogenic process as opposed to
merely developing symptomatic therapies (Savitt et al., 2006).
Genes linked to rare forms of PD or the processes that they
regulate are potential therapeutic targets (Gasser, 2009; Lees
et al., 2009). One can attempt to model PD in animals or cellular
systems using genetic manipulation, that is transgenic overex-
pression of mutant genes for autosomal-dominant genes such
as a-synuclein and leucine rich repeat kinase 2 (LRRK2) and
knockout or knockdown models for autosomal-recessive genes
such as Parkin, DJ-1, phosphatase and tensin homolog (PTEN)-
induced novel kinase 1 (PINK1). Other mutations in genes are
also causal for PD, including glucocerebrosidase (GBA) and
PD syndromes such as ATP13A2, but animal models for these
mutations have not been described or characterized. Many
different organisms and cellular models are useful for genetic
manipulation, and many of these models have been especially
helpful in dissecting the pathogenic mechanisms of PD.646 Neuron 66, June 10, 2010 ª2010 Elsevier Inc.Genetic models of neurodegenerative diseases have in
general been quite instructive in understanding the pathogenesis
of a variety of neurodegenerative disorders. Often the initial
models only replicate a portion of the disease in humans, but
as models are refined, key features of most diseases can be
replicated. In amyotrophic lateral sclerosis (ALS), there was
instant success. Overexpression of the G93A mutation in super-
oxide dismutase (SOD) created a mouse model of ALS, which
replicated key features of the illness in humans (Gurney et al.,
1994). In Alzheimer’s disease (AD), initial animal models suffered
from the lack of manifesting the full spectrum of the disease
(Kokjohn and Roher, 2009). However, refinement and optimiza-
tion of the models such as the ‘‘triple’’ transgenic model express-
ing the APP Swedish mutation K670N/M671L, the presenilin-1
M146V mutation, and the tau P301L mutation, as well as other
models provided useful tools for enhancing the molecular under-
standing of AD pathogenesis (Kokjohn and Roher, 2009). Similar
examples on either spectrum of modeling human pathogenesis
exist in other neurodegenerative diseases. Overall, modeling
human neurodegenerative diseases has been fruitful and yielded
many fresh insights into the pathogenesis of these disorders. In
particular, these models have been instructive for modeling
different stages of the corresponding illness, ranging from
insights into the early to late stage manifestations of the disease.
These models have also served as platforms to test novel thera-
peutics. In this review, we attempt to synthesize what has been
gleaned from the study of PD models. In addition, we discuss
controversies, future directions, and further work that needs to
be done to potentially optimize existing models.
PD Animal Models
Modeling PD in animals, particularly rodent models using
genetics, has been viewed as difficult. This is, in part, due to
the prevailing concept that any ‘‘reasonable’’ model of PD should
have progressive loss of DA neurons (Chesselet et al., 2008).
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ical and neuropathologic features of PD. What features should
be present in an ideal model of PD? Models should be age
dependent and progressive, since degeneration usually begins
in late adulthood in PD. In addition to the loss of DA neurons,
there should be motor dysfunction including slowness of move-
ment, rigidity, rest tremor, and postural instability that is respon-
sive to DA replacement therapy. Another key determinant of this
disorder is the presence of Lewy bodies and Lewy neurites that
contain a-synuclein and ubiquitin-proteasomal proteins among
others. However, some genetic forms of PD do not have Lewy
bodies, including some patients with parkin and LRRK2 muta-
tions. These cases may represent the exceptions that prove
the rule, since most cases of LRRK2 have a-synuclein inclusions
(Ross et al., 2006), and almost as many cases of parkin muta-
tions that have been examined have Lewy bodies as those that
do not (for review see West et al., 2007a). No neuropathologic
studies have been reported for patients with PINK1, DJ-1, and
ATP13A2 mutations, whereas mutations in GBA are associated
with Lewy bodies (Clark et al., 2009). Whether there are distinct
mechanisms that lead to neurodegeneration in the various
genetic causes of PD requires further study. The different muta-
tions in PD-associated genes may act in series and/or in parallel
pathways. However, all genetic causes of PD ultimately lead to
loss of DA neurons in the nigrostriatal pathway, and as such,
there are likely to be some common final molecular mechanisms.
Extensive neuropathologic studies clearly indicate that PD is
a global nervous system disorder with degeneration throughout
the central and peripheral nervous system (Braak et al., 2006;
Jellinger, 2009). Some neuropathologists suggest that PD
begins in the lower brainstem and olfactory bulb, with the sub-
stantia nigra only becoming affected during the middle stages
of the disease (Braak et al., 2006). Moreover, there are numerous
clinical features of PD that are not attributable to the degenera-
tion of DA neurons (Langston, 2006). PD affects many areas of
the central nervous system, including the hypothalamus, nucleus
basalis of Meynert, and the dorsal motor nucleus of the vagus, as
well as limbic and cortical areas. These nondopaminergic
features of PD are often the most disabling, as current treatment
inadequately addresses these symptoms (Savitt et al., 2006).
Currently, there are many animal models of PD due to genetic
causes in different model organisms, including mice, Drosophila
melanogaster, andCaenorhabditis elegans. There are a variety of
cellular models that have been used to glean insight into how
mutations in the various genetic causes of PD lead to neuronal
dysfunction. In addition, there are several intoxication models
that are based on selective killing of DA neurons. Several excel-
lent reviews on these animal and cellular models exist (see Bove´
et al., 2005; Chesselet et al., 2008; Gupta et al., 2008; Lim and
Ng, 2009; Moore et al., 2005; Pallanck and Whitworth, 2007;
Wong, 2007).
Cellular models offer the advantage of dissecting the molec-
ular function of the genes and proteins implicated in PD. Cellular
studies can be done relatively quickly and robustly using molec-
ular, biochemical, and pharmacologic approaches. Many
insights into the function of the proteins implicated in PD have
initially stemmed from cellular models. However, one needs to
interpret cellular studies with caution, since they are often proneto artifact and/or misinterpretation. Animal models provide the
means to study a cellular process in the context of functional
neuronal circuits in an unbiased way serving as a validation or
reality check on cellular assays. Due to the ease of genetic
manipulation (transgenics and knockouts), the mouse has
become the preferred system to model neurodegenerative
diseases such as PD. The mouse has the relatively short lifespan
of 2 years, which renders it less then ideal for modeling a disorder
like PD that takes five to seven decades or longer to manifest in
humans. Thus, with autosomal-dominant disorders, approaches
have focused on overexpression in an attempt to shorten the
time to disease manifestation in mice. Since most PD-associ-
ated genes are not overexpressed to a great extent, one needs
to interpret mouse transgenic studies with a bit of a caution as
well. Validation of findings in transgenic models has relied on
the use of human postmortem tissue. Although human post-
mortem analysis often reflects end-stage illness, footprints of
early disease pathology often remain, and it is the gold standard
by which to measure the ability of animal models to reflect actual
pathogenic processes. Occasionally, animal models provide
insight into the human condition that was not apparent from
routine neuropathological assessments. C. elegans and Dro-
sophila are powerful models to rapidly screen for pharmacologic
and genetic interventions that may modify neurodegeneration in
these models. They have some shortcomings in modeling PD,
including the lack of expressing a-synuclein and a limited reper-
toire of cell death effectors. These models offer the advantage of
identifying evolutionarily conserved pathways, but the challenge
in using these models is to verify that potential modifiers occur in
human PD.
Although genetics has generated tremendous excitement and
new energy in PD research, it is important to realize that only
about 10%–20% of PD is due to genetic causes. Sporadic PD
is characterized by mitochondrial dysfunction and oxidative
and nitrosative stress (Banerjee et al., 2009). Inhibition of
complex I of the mitochondrial electron transport chain is selec-
tively dysfunctional in DA neurons in sporadic PD (Dawson and
Dawson, 2003). DA neurons are particularly sensitive to the toxic
effects of mitochondrial complex I toxins, such as rotenone or 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Banerjee
et al., 2009; Dauer and Przedborski, 2003). There are a variety
of intoxication models of PD, and their use has provided the
framework for improvements in symptomatic medical and
surgical therapies for PD. How these toxins cause selective
loss of DA neurons is reviewed elsewhere (Banerjee et al.,
2009; Dauer and Przedborski, 2003). Unfortunately, no neurore-
generative or neuroprotective agent identified from studies in the
PD intoxication models has been shown to be efficacious in PD
patients. The lack of the predictive value of the PD-intoxication
models may be due to the acuteness of these models and their
failure to replicate all the features of PD. As such, there is tremen-
dous hope that models based on gene mutations that are linked
to PD may provide the proper context by which to ultimately
develop therapies that are proven to be neuroprotective or neu-
roregenerative in humans with PD.
Models of Autosomal-Dominant PD
Currently, there are two autosomal-dominantly inherited
causes of PD. Mutations in a-synuclein cause one form ofNeuron 66, June 10, 2010 ª2010 Elsevier Inc. 647
Table 1. Key Features of Autosomal-Dominant (a-Synuclein and LRRK2) Models*
Model
Neuronal Loss Dopamine
(DA) Non-Dopamine
(Non-DA)
L-DOPA-Responsive
Motor Deficits
Mitochondrial
Dysfunction
Lewy Body -
like Inclusions
Suitability for
Testing Disease
Modifying Therapy
a-synuclein
Drosophila
(WT, A30P, A53T)
DA+
Non-DA–
+ ND + +
Mouse Thy1
(WT, A30P, A53T)
DA–
Non-DA+
ND ND - (nonfibrillar
a-synuclein inclusions)
+ (A30P, A53T)
Mouse PrP
(WT, A30P, A53T)
DA–
Non-DA+
ND + + + (A53T)
Rat AAV
(WT, A53T)
DA+
Non-DA–
+ ND – (nonfibrillar
a-synuclein inclusions)
+ (A53T)
LRRK2
Drosophila
(WT, I1122V,
Y1699C, G2019S,
I2020T, G2385R)
DA+
Non-DA–
+ ND - +
Mouse BAC (R1441G) DA– (YTH)
Non-DA–
+ ND – maybe
Autosomal–dominant models of PD with evidence of progressive neurodegeneration in either dopamine (DA) or nondopaminergic (Non-DA) systems
are highlighted. Features common to sporadic PD are indicated, including age-dependent, progressive degeneration of DA and non-DA systems, levo-
dopa (L-dopa) responsive motor deficits, the presence of Lewy body inclusions that contain filamentous a-synuclein and mitochondrial dysfunction
(see text). The suitability of the various models for testing disease-modifying therapy is also indicated. *Not all animal models are listed for a-synuclein
and LRRK2.
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a-synuclein, the first gene linked to familial PD, changed the
nature and scope of PD research. It catalyzed the identification
of several other PD-linked genes and fueled research in PD.
a-Synuclein’s presence in Lewy bodies and neurites, two key
pathologic hallmarks of PD, illustrates the intimate relationship
between familial and sporadic PD and how studying familial PD
leads to fresh insights into sporadic PD. It was the genetic
discovery of a-synuclein linkage to PD that led to the discovery
that a-synuclein was the major structural moiety of Lewy
bodies and neurites (Goedert, 2001). Mutations in LRRK2 are
the most frequent genetic cause of autosomal-dominant PD
(Paisa´n-Ruı´z et al., 2004; Zimprich et al., 2004). It also appears
to play a prominent role in sporadic PD as well, since mutations
in LRRK2 account for up to 4% of sporadic PD (Albrecht, 2005).
Several animal and cellular models of a-synuclein and LRRK2
have been reported, and they have provided important insight
into how mutations in a-synuclein and LRRK2 may lead to neu-
rodegeneration in PD (Table 1). Central to the utility and predic-
tive value of these models is whether they can replicate some
of the key feature of PD, including age-dependent neurodegen-
eration, the presence of Lewy bodies, DA neuronal death, mito-
chondrial dysfunction, and other features of PD.
Three point mutations in a-synuclein (A53T, A30P, and
E46K) cause familial PD (Figure 1) (Gasser, 2009; Lees et al.,
2009). Mutations in a-synuclein are 100% penetrant and
a rare cause of PD. In addition, simple duplication or triplica-
tion of a-synuclein itself is sufficient to cause PD, suggesting
that the level of expression of a-synuclein is a critical determi-
nant of PD progression (Singleton, 2005; Singleton et al.,
2003). Indeed, it seems that one’s relative risk for developing648 Neuron 66, June 10, 2010 ª2010 Elsevier Inc.PD is determined by polymorphisms in the promoter or 30-
UTR, which determine the level of a-synuclein. Individuals
with a high level of a-synuclein have a greater risk of devel-
oping PD than those with a lower level of a-synuclein (Winkler
et al., 2007). Recent genome-wide association studies further
support the notion that a-synuclein is critically linked to PD, as
there is an association between PD and a-synuclein (Suther-
land et al., 2009).
a-Synuclein is an abundant presynaptic phosphoprotein that
normally exits in an unstructured state. It may be involved in
intracellular trafficking within the endoplasmic reticulum/Golgi
network, since overexpression of a-synuclein in Drosophila
and yeast disrupts cargo trafficking in this network (Cooper
et al., 2006; Gitler et al., 2008). Toxic misfolded forms of a-syn-
uclein appear to play a prominent role in cell death (Figure 1)
(for review see Cookson, 2005; Gupta et al., 2008; Lee and
Trojanowski, 2006). Mutations in a-synuclein increase the
propensity for misfolding. A number of factors that are thought
to play a prominent role in sporadic PD, including oxidative and
nitrosative stress and mitochondrial dysfunction, also increase
the propensity for a-synuclein misfolding (Figure 1). a-Synuclein
exists in a variety of higher-ordered structures, including oligo-
mers, protofibrils, fibrils, and filaments where protofibrils and
fibrils seem to be the most toxic forms (Lee and Trojanowski,
2006). Stabilization of these higher-ordered structures maybe
central to the pathogenesis of PD. Disease severity and the
propensity to form higher-ordered structures correlate with
truncation of a-synuclein into more toxic forms (Li et al.,
2005). Misfolded a-synuclein also contributes to other neurode-
generative disorders designated a-synucleinopathies, and they
are broadly defined as disorders with misfolding of a-synuclein
Figure 1. Mechanisms of Autosomal-
Dominant PD
Mutations (A53T, A30P, E46K) or increased levels
(triplication or duplication) of a-synuclein lead to
aggregation and fibrillization. Features common
to sporadic PD such as nitric oxide (NO), reactive
oxygen species (ROS), and mitochondrial
dysfunction also lead to a-synuclein aggregation.
Agents or genetic modifications that inhibit a-syn-
uclein aggregation are protective, whereas
enhancing a-synuclein aggregation promotes
neurodegeneration. Truncation of a-synuclein
accelerates aggregation and participates in the
degenerative process. a-Synuclein is degraded
by both the ubiquitin proteasome system and the
autophagic/lysosomal system. Mutant and aggre-
gated forms of a-synuclein inhibit the UPS and the
autophagic/lysosomal system as well as the mito-
chondria setting in motion feed forward cycles
(indicated by green circular arrows) of enhanced
accumulation and aggregation of a-synuclein
(see text). LRRK2 mutations (G2019S, R1441C/
G/H, Y1699C, and I2020T) lead to neurodegener-
ation that is kinase dependent and GTP-binding
dependent (data not shown). LRRK2 shares some pathogenic mechanisms with PD due to a-synuclein since a consistent pathologic feature of patients with
LRRK2 mutations is the presence of a-synuclein inclusions through unclear mechanisms (?). Mitochondrial dysfunction enhances LRRK2 neurodegeneration
in some models through unclear mechanisms (?). Glucocerebrosidase and ATP13A2 genetically interact with a-synuclein and also share common pathogenic
mechanisms (data not shown).
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(Lee and Trojanowski, 2006).
Due to a-synuclein’s prominent role in PD and related a-synu-
cleinopathies, many a-synuclein models using a variety of
approaches have been created and extensively characterized
(Table 1). Overexpression of WT, A53T, and A30P a-synuclein
inDrosophila recapitulated many characteristics of PD, including
age-dependent selective DA neuron loss, Lewy body-like fila-
mentous inclusions containing a-synuclein, and DA-responsive
locomotor deficits (Feany and Bender, 2000), although whether
there is actual loss of DA neurons or just loss of DA markers is
not clear (Pesah et al., 2005). C. elegans overexpressing a-syn-
uclein have loss of DA neurons, but they lack significant a-synu-
clein inclusions, and the degeneration of DA neurons is not
progressive (Kuwahara et al., 2006; Lakso et al., 2003). The
strength of the Drosophila model is that it is the only a-synuclein
animal model with possible progressive degeneration of DA
neurons. Drosophila and C. elegans lack the complexity of verte-
brates, and they do not express a-synuclein, thus they are imper-
fect models of PD. Moreover, these models fail to exhibit the
cardinal clinical features of PD (bradykinesia, rest tremor,
rigidity, and postural instability), and thus their value mainly lies
in identifying genetic and pharmacologic modifiers of a-synu-
clein-induced neurodegeneration. As noted above, the chal-
lenge is to verify that potential modifiers uncovered in
these simple model systems are evolutionarily conserved in
human PD.
Knockout of a-synuclein indicates that it plays little if any role
in the development or maintenance of DA neurons (Abeliovich
et al., 2000; Chandra et al., 2004); thus, loss of some critical func-
tion of a-synuclein is unlikely to play a role in the pathogenesis of
a-synuclein-induced neurodegeneration. However, this has not
been settled, since a-synuclein may function as a cochaperone
as transgenic expression of a-synuclein abolishes the lethalityand neurodegeneration caused by deletion of the synaptic
vesicle chaperone, cysteine-string protein-a (Chandra et al.,
2005). Thus, a-synuclein may play a role in protecting nerve
terminals from injury, and sequestering a-synuclein into aggre-
gates could eliminate this protective function.
A number of a-synuclein transgenic mice have been reported
using a variety of promoters (Table 1). The phenotypic outcome
of a-synuclein overexpression in mice heavily depends on the
promoters used to drive transgene expression (Chesselet,
2008). None of these models accurately represent PD, in that
there is no progressive loss of DA neurons. Despite the lack of
overt degenerative pathology in DA neurons, in the various
mouse a-synuclein models there are several functional abnor-
malities in the nigrostriatal system, some of which are DA
responsive (see Chesselet, 2008; Chesselet et al., 2008). More-
over, most of these models are excellent models of a-synu-
clein-induced neurodegeneration.
The toxicity of aggregated a-synuclein seems to occur
through mitochondrial dysfunction and proteasomal and lyso-
somal impairments and disruption of ER-Golgi trafficking,
which set forth feed-forward mechanisms of further injury
(Figure 1) (Cooper et al., 2006; Cuervo et al., 2004; Martin
et al., 2006; Tanaka et al., 2001). The link to mitochondrial
dysfunction is particularly attractive as decrements in mito-
chondrial complex I is a consistent feature of sporadic PD
(Schapira, 2008). Moreover, inhibition of mitochondrial complex
I can lead to selective DA neurodegeneration (Banerjee et al.,
2009). Although impairment of the proteasomal and lysosomal
systems can lead to a-synuclein accumulation consistent with
a role of these systems in catabolizing a-synuclein, inhibition
of the proteasomal and lysosomal systems leads to general
neurodegeneration without selectivity for any particular
neuronal system (Bedford et al., 2008; Komatsu et al., 2006).
Thus, in contrast to mitochondrial complex I inhibition, whichNeuron 66, June 10, 2010 ª2010 Elsevier Inc. 649
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pathogenesis of PD, impairment of the proteasomal and lyso-
somal systems are likely to be the consequence of the degen-
erative process set in motion by PD.
There appears to be an intimate relationship between a-synu-
clein and mitochondrial function. DA neurons in a-synuclein
knockouts are resistant to the DA neurotoxin MPTP and other
mitochondrial toxins (Dauer and Przedborski, 2003; Klivenyi
et al., 2006). In addition, mice overexpressing a-synuclein are
more sensitive to paraquat, another mitochondrial toxin (Norris
et al., 2007). Transgenic mice overexpressing human A53T
a-synuclein exhibit mitochondrial abnormalities including mito-
chondrial DNA damage and degeneration (Martin et al., 2006).
DA neurons progressively degenerate and accumulate intra-
neuronal inclusions that contain a-synuclein in DA-specific mito-
chondrial transcription factor A (TFAM) knockouts (Ekstrand
et al., 2007). Moreover, the substantia nigra and striatum, but
not the cerebellum, of PD patients accumulate a-synuclein in
the setting of decreased mitochondrial complex I activity (Devi
et al., 2008), and patients with mitochondrial mutations have
Lewy bodies (Betts-Henderson et al., 2009). Since mitochondrial
dysfunction causes a-synuclein aggregation and a-synuclein is
capable of injuring the mitochondria, there is a feed-forward
loop that has the potential to set in motion the progressive unre-
lenting degeneration of PD (Figure 1). Understanding the
relationship of a-synuclein and mitochondrial dysfunction is
important since it may provide insight into the causes of sporadic
PD and lead to new disease-modifying therapies.
Of the many vertebrate models, only the mouse prion
promoter (mPrP) A53T a-synuclein transgenic mice exhibit the
full range of a-synuclein pathology that is observed in humans,
including a-synuclein aggregation, fibrils and truncation, a-syn-
uclein phosphorylation and ubiquitination, and progressive
age-dependent neurodegeneration (Chesselet, 2008; Dawson
et al., 2002; Giasson et al., 2002; Lee et al., 2002). The other
transgenic models exhibit gradations of a-synuclein aggrega-
tion, but they lack the characteristic a-synuclein fibrils that are
present in humans with PD and related a-synucleinopathies.
Studies indicate that assembly of a-synuclein into higher-order
structures is one of the critical events that contribute to neurode-
generation (Lee and Trojanowski, 2006). Mutant forms of a-syn-
uclein accelerate the formation of aggregates (Conway et al.,
1998). From the transgenic a-synuclein mouse models it is clear
that neuronal dysfunction and degeneration is probably initiated
by the prefibrillar oligomers, as models exhibiting only prefibrillar
oligomers display features of neurodegeneration (Chandra et al.,
2005; Freichel et al., 2007; Neumann et al., 2002; Rockenstein
et al., 2002; van der Putten et al., 2000). Fibrils of a-synuclein
also play a role in the toxicity since the formation of a-synuclein
aggregates is required for significant neurodegeneration
(Giasson et al., 2002; Lee et al., 2002; Periquet et al., 2007).
However, some studies suggest that sequestration of a-synu-
clein into fibrils may be protective (see Forman et al., 2005). In
any event, strategies aimed at maintaining or converting a-syn-
uclein into its monomeric state have a high potential to be ther-
apeutic. Mouse models with prefibrillar oligomers versus fibrillar
a-synuclein could be used to test the efficacy of strategies
focused on converting or maintaining a-synuclein in a monomeric650 Neuron 66, June 10, 2010 ª2010 Elsevier Inc.state. Since humans with PD express the full spectrum of a-syn-
uclein aggregation, therapeutic trials in animal models that also
display the full complement of a-synuclein pathology are likely
to be the most predictive.
Several mutations in LRRK2 cause autosomal-dominant PD
(Figure 1). LRRK2 is a large multidomain-containing protein
that is localized to membranous structures (Biskup et al.,
2006). Mutations that segregate with PD are concentrated in
the GTPase and kinase domains (Biskup and West, 2009). The
most common mutation, G2019S, has a frequency of 1% of
patients with sporadic PD and 4% of patients with hereditary
PD (Healy et al., 2008). The risk of PD for a person with an
LRRK2 G2019S mutation increases with age, and it is 28% at
59 years, 51% at 69 years, and 74% at 79 years (Healy et al.,
2008). The majority of cases of LRRK2-related PD that have
come to autopsy are characterized pathologically by the pres-
ence of a-synuclein inclusions, suggesting that LRRK2 and
a-synuclein share common pathogenic mechanisms, but cases
have been described with only neuronal loss or ubiquitin or tau
inclusions (Ross et al., 2006). LRRK2 may play a role in neuronal
outgrowth and guidance (MacLeod et al., 2006; Sakaguchi-Na-
kashima et al., 2007), but its normal physiologic function, phos-
phosubstrates, binding partners, and regulators of kinase and
GTPase activity have yet to be confirmed or clarified. In cellular
models, overexpression of disease-causing mutations of
LRRK2 are toxic, and the toxicity is kinase and GTP-binding
dependent (Greggio et al., 2006; Smith et al., 2006; West et al.,
2007b). Thus, LRRK2 kinase inhibitors and modulators of GTP
binding may be therapeutic.
Overexpression of LRRK2 in Drosophila leads to age-depen-
dent DA-responsive reductions in locomotor activity and loss
of DA neurons (Table 1) (Liu et al., 2008; Ng et al., 2009; Vender-
ova et al., 2009). In a similar manner, overexpression of LRRK2
leads to degeneration of DA neurons in C. elegans (Saha et al.,
2009). Like the Drosophila and C. elegans a-synuclein models,
the LRRK2 models in these simpler model systems are imper-
fect. Since Drosophila and C. elegans do not express a-synu-
clein and a prominent feature of PD caused by mutations in
LRRK2 is a-synuclein pathology, the utility of studying mecha-
nisms of LRRK2 neurodegeneration in flies and worms is poten-
tially problematic. Their value mainly lies in identifying genetic
and pharmacologic modifiers of LRRK2-induced neurodegener-
ation. Potential modifiers uncovered in these simple model
systems will need to be carefully validated to determine whether
they are evolutionarily conserved in human PD.
Knockout of LRRK homologs inDrosophila andC. elegans and
knockout of LRRK2 in mice suggest that LRRK2 plays little if any
role in the development or maintenance of DA neurons, although
there are disparate results in the Drosophila studies (Andres-
Mateos et al., 2009; Imai et al., 2008; Lee et al., 2007; Sakaguchi-
Nakashima et al., 2007; Wang et al., 2008a). In contrast to the
cellular and Drosophila models, current transgenic mouse
models are not very robust PD models (Table 1). Bacterial artifi-
cial chromosome (BAC) transgenic mice expressing LRRK2 WT,
LRRK2 R1441G, LRRK2 G2019S have minimal evidence of neu-
rodegeneration (Li et al., 2009, 2010). Conditional expression of
LRRK2 WT and LRRK2 G2019S also failed to exhibit neurode-
generation of DA neurons, but LRRK2 was expressed at low
Table 2. Key Features of Autosomal-Recessive (parkin, PINK1, DJ-1) Models*
Model
Neuronal Loss Dopamine
(DA) Non-Dopamine
(Non-DA)
L-DOPA
Responsive
Motor Deficits
Mitochondrial
Dysfunction
Lewy Body-like
Inclusions
Suitability for
Testing Disease
Modifying Therapy
Parkin
Drosophila (KO) DA+
Non-DA–
+ + – +
Mouse (KO) DA–
Non-DA–
ND + – –
Mouse
(BAC-DAT-Q311X)
DA+
Non-DA–
ND ND + maybe
PINK1
Drosophila (KO) DA+
Non-DA–
+ + – +
Mouse (KO) DA–
Non-DA–
ND + – –
DJ-1
Drosophila (KO) DA+
Non-DA–
+ + – +
Mouse (KO) DA–
Non-DA–
ND + – –
Autosomal-recessive models of PD are highlighted. Features common to sporadic PD are indicated, including age-dependent, progressive degener-
ation of DA and non-DA systems, levodopa (L-dopa) responsive motor deficits, the presence of Lewy body inclusions that contain filamentous a-syn-
uclein and mitochondrial dysfunction (see text). The suitability of the various models for testing disease-modifying therapy is also indicated. *Not all
animal models are listed for parkin, PINK1, DJ-1.
Neuron
Reviewlevels in DA neurons due to the use of the calcium/calmodulin-
dependent protein kinase IIa (CamKII) promoter (Lin et al.,
2009; Wang et al., 2008c). When the R1441C mutation is ex-
pressed under the control of the endogenous regulatory
elements, by knockin of the R1441C mutation, there is no degen-
eration of DA neurons (Tong et al., 2009). Most of the current
LRRK2 transgenic mice have abnormalities in the nigrostriatal
system, such as stimulated DA neurotransmission or behavioral
deficits, which are DA responsive. These abnormalities probably
represent some of the earliest neuronal dysfunction that is set in
motion by pathogenic LRRK2 mutations. In contrast to the other
LRRK2 transgenic models, the LRRK2 R1441G BAC transgenic
mice have progressive age-dependent motoric deficits leading
to immobility that are levodopa and apomorphine responsive,
despite no substantial neurodegeneration (Li et al., 2009).
LRRK2 and a-synuclein are likely to share common pathogenic
mechanisms, as overexpression of LRRK2 greatly enhanced
and knockout of LRRK2 reduced the neuropathologic abnormal-
ities in A53T a-synuclein transgenic mice (Lin et al., 2009).
Why the mouse LRRK2 transgenic models do not exhibit more
substantial pathology is not clear. It may relate to the fact that
LRRK2 mutations in humans are only partially penetrant and
that there may need to be other genetic and/or environmental
hits that are required for degeneration of DA neurons (see below).
The BAC and knockin models express mutant LRRK2 during
development and thus there may be compensatory mechanisms
in the mouse that prevent loss of DA neurons (see below). The
utility of the current models is likely to be focused on how muta-
tions in LRRK2 lead to early dysfunction of the nigrostriatal DA
system. It is unlikely that these models could be used to test neu-
roprotective agents, since there is no neurodegeneration.Models of Autosomal-Recessive PD
There are currently four autosomal-recessive causes of PD.
Mutations in parkin were first identified as the genetic cause of
autosomal-recessive juvenile Parkinsonism in Japanese families
(Kitada et al., 1998). More than 100 mutations in parkin have
been reported, accounting for 50% of familial PD cases and at
least 20% of young-onset sporadic PD (Lu¨cking et al., 2000).
Mutations in PINK1, the second most common autosomal-
recessive mutation following parkin contributes to almost 1%–
7% of early-onset PD (Gasser, 2009). Mutations in DJ-1 are
a rare cause of PD (Heutink, 2006). A number of animal and
cellular models have been described for parkin, PINK1, and
DJ-1, which have led to tremendous insight into the role these
proteins play in PD. In contrast, no animal models have been re-
ported for ATP13A2, which is another rare cause of PD (Ramirez
et al., 2006). Similar to the autosomal-dominant models, the
Drosophila models of autosomal-recessive PD exhibit age-
dependent loss of DA neurons and other abnormalities, whereas
the mouse models fail to replicate many key features of PD
(Table 2).
Parkin functions as an E3 ubiquitin ligase where it participates
in the ubiquitin proteasome system (Figure 2) (Shimura et al.,
2000; Zhang et al., 2000). Parkin is a huge gene with 12 exons
that span 1.3 Mb of genomic DNA encoding a 465 amino acid
protein, which may account for the high degree of mutations.
Penetrance appears to be complete in individuals who have
two disease-causing mutations in Parkin (Lu¨cking et al., 2000).
Disease-causing mutations in parkin for the most part lead to
a loss of its E3 ubiquitin ligase activity. Although parkin dysfunc-
tion plays a critical role in the general pathogenesis of early-
onset Parkinsonism, it may also play a role in sporadic PDNeuron 66, June 10, 2010 ª2010 Elsevier Inc. 651
Figure 2. Mechanisms of Autosomal-
Recessive PD
Loss-of-function mutations in PINK1, parkin, and
DJ-1 cause PD. PINK1 is a mitochondrial kinase
in which mutations impair its kinase activity.
PINK1 acts upstream of parkin to ultimately impair
mitochondrial function through as yet unknown
mechanisms. Parkin is inactivated by genetic
mutations or nitric oxide (NO), reactive oxygen
species (ROS), dopamine (DA), or in sporadic
PD, which impairs parkin’s ubiquitin E3 ligase
activity. This either leads to accumulation of an
as of yet unidentified pathogenic substrate or it
impairs ubiquitin-dependent signaling that ulti-
mately lead to mitochondrial dysfunction and neu-
rodegeneration. Mutations in DJ-1 lead to a loss of
its chaperone activity as well as impairing its
peroxidase activity among other functions, which
ultimately leads to mitochondrial dysfunction and
neurodegeneration.
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nergic, oxidative, and nitrosative stress, which play key roles in
sporadic PD (Chung et al., 2004; LaVoie et al., 2005; Yao et al.,
2004).
It has been difficult to build a consensus and unifying theory on
how parkin dysfunction leads to neurodegeneration in PD.
Numerous putative substrates for parkin have been reported
(for review see Dawson and Dawson, 2010; West et al., 2007a).
No consensus has emerged on which of these potential parkin
substrates may play a pathogenic role in parkin deficiency. Par-
kin is capable of modifying proteins with different ubiquitin link-
ages, including monoubiquitination and polyubiqutination using
both lysine-48 and lysine-63 linkages. Monoubiquitination may
be involved in receptor turnover, lysine-63 linkages may be
involved with protein inclusions, and lysine-48 linkages regulate
protein degradation (Dawson and Dawson, 2010). Under-
standing these alternative ubiquitination reactions by parkin
may ultimately turn out to be important in the pathogenesis of
PD due to parkin inactivation.
Knockout of parkin in Drosophila leads to mutant flies with
reduced lifespan, male sterility, and severe defects in both flight
and climbing abilities (Greene et al., 2003; Whitworth et al.,
2005). In addition, there are muscle and sperm mitochondrial
defects that ultimately result in cell death with apoptotic
morphology. Parkin mutant flies show significant indirect flight
muscle degeneration with reduced muscular fibrils and reduced
mitochondria with a significant loss of cristae structure.
Decreased TH levels were observed in aged flies, and careful
examination revealed that a subset of DA neurons degenerate
(Table 2). Parkin null mutants display DA-responsive locomotion
deficits. In contrast, none of the parkin knockout mice have any
substantial dopaminergic or behavioral abnormalities (Table 2)
(Goldberg et al., 2005; Itier et al., 2003; Perez and Palmiter,
2005; Von Coelln et al., 2004). Some of the parkin knockout
mice have subtle abnormalities in the either the DA nigrostriatal
circuit or the locus coeruleus noradrenergic system (Goldberg652 Neuron 66, June 10, 2010 ª2010 Elsevier Inc.et al., 2005; Von Coelln et al., 2004). Interestingly overexpression
of mutant human parkin in both Drosophila and mice leads to
progressive degeneration of DA neurons, supporting the idea
that some parkin mutants might act in a dominant-negative
fashion (Lu et al., 2009; Sang et al., 2007; Wang et al., 2007).
PD due to PINK1 mutations is inherited in a recessive fashion,
and mutations are thought to lead to a loss of function (Valente
et al., 2004). Penetrance appears to be complete in individuals
who have two disease-causing mutations in PINK1 (Gasser,
2009). Structurally, PINK1 contains a conserved serine/threonine
kinase domain with an N-terminal mitochondrial targeting motif
(Figure 2). PINK1 is localized to the mitochondrial intermembrane
space and membranes of the mitochondria (Silvestri et al., 2005),
but a recent topology study suggests that the kinase domain
of PINK1 faces the cytosol (Zhou et al., 2008). Thus, phy-
siologic PINK1 kinase substrates may need to reside in the
cytosol. PINK1 may regulate mitochondrial calcium dynamics
(Gandhi et al., 2009), but additional studies are required to iden-
tify/confirm authentic physiologic and pathophysiologic PINK1
substrates and clarify the site of action of PINK1.
Drosophila lacking PINK1 exhibit male sterility, an inability to
fly, and a slower climbing speed (Clark et al., 2006; Park et al.,
2006). Accompanying these behavioral deficits was mitochon-
drial degeneration leading to apoptosis in flight muscles. Similar
to Drosophila lacking parkin, the mitochondria were swollen with
reduced ATP levels, mitochondrial DNA, and mitochondrial
proteins. DA neurons exhibited a small, but significant reduction
in number with enlarged mitochondria (Table 2). Similar to parkin
knockout mice, PINK1 knockout mice did not exhibit any major
abnormality (Table 2) (Gautier et al., 2008; Gispert et al., 2009;
Kitada et al., 2007). In particular, the number of DA neurons, the
level of striatal DA, and the level of DA receptors are unchanged.
Like the parkin knockouts, there are deficits in nigrostriatal DA
neurotransmission (Kitada et al., 2007). Both parkin and PINK1
knockouts also have mild mitochondrial defects (Gautier et al.,
2008; Palacino et al., 2004).
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phenotypic similarities with parkin mutant flies (Clark et al., 2006;
Park et al., 2006). Transgenic expression of parkin ameliorated
PINK1 loss-of-function phenotypes, whereas transgenic expres-
sion of PINK1 had no effect on parkin loss-of-function pheno-
types (Clark et al., 2006; Park et al., 2006). Thus, parkin and
PINK1 function in a common pathway, with PINK1 functioning
upstream from parkin. Additional studies suggest that parkin
and PINK1 regulate mitochondrial trafficking and/or autophagy
(Deng et al., 2008; Narendra et al., 2010; Poole et al., 2008;
Vives-Bauza et al., 2010; Yang et al., 2008). It is likely that there
is a common PINK1 and parkin substrate that is positioned
between PINK1 and parkin that is important for mitochondrial
function (Figure 2). Studies focused on the interplay between
PINK1 and parkin and the identification of a common interme-
diary between PINK1 and parkin have tremendous promise to
advance the understanding of how mutations in these genes
cause PD.
DJ-1 is a member of the ThiJ/PfpI family of molecular chaper-
ones (Gasser, 2009; Moore et al., 2006), and mutations in DJ-1
play a small but important role in early-onset Parkinsonism
(Bonifati et al., 2003). Penetrance appears to be complete in indi-
viduals who have two disease-causing mutations in DJ-1
(Heutink, 2006). PD-associated mutations in DJ-1 produce loss
of function of DJ-1 by instability leading to defective dimer
formation or lack of expression (Macedo et al., 2003; Moore
et al., 2003). DJ-1 is normally expressed widely throughout the
body and is subcellularly localized to the cytosol, mitochondrial
matrix, and intermembrane space (Zhang et al., 2005). DJ-1 is
a redox-sensitive molecular chaperone with a variety of diverse
functions (Cookson, 2005; Kahle et al., 2009; Moore et al.,
2006). In cellular models, it regulates redox-dependent kinase
signaling pathways and acts as a regulator of antioxidant gene
expression (for review see Kahle et al., 2009). DJ-1 functions
in vivo as an atypical peroxiredoxin-like peroxidase, where it
protects against oxidative stress in mitochondria (Figure 2)
(Andres-Mateos et al., 2007). DJ-1 also functions as redox-
sensitive RNA-binding protein (van der Brug et al., 2008). Consis-
tent with its role as a chaperone, DJ-1 is thought to have a variety
of other pleiotropic functions (for review see Cookson, 2005;
Kahle et al., 2009; Moore et al., 2006).
In contrast to mammalian species, which contain a single DJ-1
gene, Drosophila possess two orthologs of DJ-1: DJ-1a and DJ-
b. Many different DJ-1 Drosophila models have been generated
to explore the contribution of DJ-1 dysfunction in the pathogen-
esis of PD (Menzies et al., 2005; Meulener et al., 2005; Park et al.,
2005; Yang et al., 2005). DJ-1 double null flies for both DJ-1
homologs, DJ-1a and DJ-1b, are viable, fertile, and have normal
number of DA neurons and lifespan. Acute knockdown of DJ-1
by transgenic RNAi led to a robust neurodegeneration, and
selective transgenic targeting of DJ-1 RNAi to DA neurons led
to age-dependent loss of DA neurons in the dorsomedial cluster
(Table 2) (Yang et al., 2005). Similar to parkin and PINK1
knockout mice, DJ-1 knockout mice do not exhibit any major
abnormality (Table 2) (Andres-Mateos et al., 2007; Chen and
Feany, 2005; Goldberg et al., 2005; Kim et al., 2005). In partic-
ular, the number of DA neurons, the level of striatal DA, and the
level of DA receptors are unchanged. Abnormalities in dopamineneurotransmission in the nigrostriatal circuit and mitochondrial
dysfunction was observed in some DJ-1 knockout animals,
similar to parkin and PINK1 knockouts (Andres-Mateos et al.,
2007; Goldberg et al., 2005; Kim et al., 2005).
Since the current parkin, PINK1, or DJ-1 knockout mice
models do not exhibit nigrostriatal pathology, at the very best
they only represent models of the earliest changes that might
occur due to parkin, PINK1, or DJ-1 deficiency. The utility of these
current autosomal-recessive models is how parkin, PINK1, or
DJ-1 deficiency lead to early dysfunction of the nigrostriatal DA
system. These models cannot be used to test neuroprotective
agents since there is no neurodegeneration. Optimization of
these models may be possible through conditional approaches
as discussed below. The study of transgenic mice overexpress-
ing mutant human parkin maybe an attractive alternative to parkin
deficiency models for understanding neurodegeneration and
therapeutic studies (Lu et al., 2009; Sang et al., 2007; Wang
et al., 2007). Although the Drosophila loss-of-function models
of PINK1 and parkin have dramatic phenotypes, the major abnor-
malities reside outside the nervous system. Moreover, the DA
system is only mildly affected. The only abnormalities that
humans with PD share with the Drosophila PINK1 and parkin
loss-of-function models is the loss of DA neurons; thus, these
models are imperfect at best. Most of the DJ-1 Drosophila defi-
ciency models are limited as well. Thus, the utility of studying
mechanisms of DA neurodegeneration in these models is
constrained. Their value mainly lies in identifying genetic and
pharmacologic modifiers of parkin, PINK1, or DJ-1 deficiency-
induced neurodegeneration. The parkin and PINK1 deficiency
models offer the ability to identify potentially evolutionarily
conserved regulators of mitochondrial function. The challenge
is to verify that potential modifiers uncovered in these simple
model systems are evolutionarily conserved in human PD.
Why Don’t DA Neurons Degenerate in Mouse
Models of PD?
Since mutations in a-synuclein are 100% penetrant and pene-
trance appears to be complete in individuals who have two
disease-causing mutations in parkin, PINK1, or DJ-1, it is
puzzling why there is no meaningful neurodegeneration of DA
neurons in mouse models of PD. Attempts to generate a-synu-
clein transgenic mice with progressive loss of DA neurons using
a variety of approaches, including transgenic mice expressing C-
terminal truncated, aggregation prone, a-synuclein (Daher et al.,
2009; Tofaris and Spillantini, 2005; Wakamatsu et al., 2008),
conditional expression of a-synuclein (Lin et al., 2009; Nuber
et al., 2008), crossing a-synuclein transgenics to parkin knock-
outs (von Coelln et al., 2006) and DJ-1 knockouts (Ramsey
et al., 2010), and overexpressing a-synuclein with DA-specific
promoters have not been very fruitful (Daher et al., 2009;
Matsuoka et al., 2001; Richfield et al., 2002; Thiruchelvam
et al., 2004). Triple knockout of parkin, PINK1, and DJ-1 have
minimal effects on DA neurons similar to the single knockout of
each gene (Kitada et al., 2009). Perhaps mouse DA neurons
are particularly resistant to overexpression of a-synuclein and
LRRK2 and the absence of parkin, PINK1, or DJ-1 due to the
expression of intrinsic protective factors or other genetic modifi-
cations that render them resistant to toxic properties of theseNeuron 66, June 10, 2010 ª2010 Elsevier Inc. 653
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ties to the MPTP intoxication model of PD (Hamre et al., 1999).
Thus, it is possible that the lack of degeneration of DA neurons
in these different mouse models may be due to common intrinsic
genetic factors in the different mouse strains utilized in these
experiments. Future studies could focus on changing the genetic
background of these models in an attempt to generate models
with loss of DA neurons.
Genetic background may not be the sole factor accounting for
the resistance of DA neurons to degeneration. For instance,
overexpression of a-synuclein via viruses is capable of eliciting
neurodegeneration of DA neurons (Table 1) (Kirik et al., 2003;
Lo Bianco et al., 2002). What might account for the sensitivity
of DA neurons to viral overexpression of a-synuclein but resis-
tance of DA neurons to overexpression of a-synuclein using
transgenic approaches? All the promoters used to drive expres-
sion of a-synuclein primarily drive expression in neurons, with
very little expression in glia (Chesselet, 2008; Chesselet et al.,
2008). Adeno-associated virus, which was used in the a-synu-
clein viral models, drives expression in both neurons and glia
(Kirik et al., 2003; Lo Bianco et al., 2002). Thus, it is possible
that a-synuclein may need to be expressed in both neurons
and glia to elicit neurodegeneration of DA neurons, with both
non-cell-autonomous and cell-autonomous processes contrib-
uting to the demise of DA neurons. Consistent with this notion
is that non-cell-autonomous processes contribute to the degen-
eration of DA neurons in the MPTP-intoxication model through
microglial-derived neurotoxins (Liberatore et al., 1999). Interest-
ingly, fetal mesencephalic DA transplants into patients with PD
developed a-synuclein-positive Lewy body-like inclusions,
strongly suggesting that PD pathology was somehow trans-
ferred from the host to the transplant tissue (Kordower et al.,
2008; Li et al., 2008). Whether this occurs through direct transfer
of a-synuclein from affected to neighboring neurons through
endocytosis (Desplats et al., 2009) or in response to the
surrounding activated glia requires further study. However,
only the transplants that had extensive microglial infiltration ex-
hibited pathology, suggesting that non-cell-autonomous
processes were contributing to the pathology in the transplanted
neurons (Dawson, 2008; Mendez et al., 2008). Microglia produce
reactive oxygen and nitric oxide species, which are known to
accelerate a-synuclein aggregation; thus, activated microglia
may contribute to disease progression by setting in motion
a self-perpetuating cycle of a-synuclein aggregation followed
by cell injury.
Since there is incomplete penetrance of LRRK2 disease-
causing mutations in humans, the lack of substantial DA neuro-
degeneration in the LRRK2 mouse models, maybe due to
genetic factors. Alternatively, environmental factors may
contribute to LRRK2-induced PD. Consistent with this notion is
the observation that toxins such as the mitochondrial complex
I inhibitors exacerbate neurodegeneration in Drosophila and C.
elegans models of LRRK2-PD (Figure 2) (Ng et al., 2009; Saha
et al., 2009). Although mutations in a-synuclein are 100% pene-
trant and penetrance appears to be complete in individuals who
have two disease-causing mutations in parkin, PINK1, or DJ-1,
environmental stressors may also play a role by accelerating
the disease process. In addition, environmental stressors may654 Neuron 66, June 10, 2010 ª2010 Elsevier Inc.contribute to PD in patients with polymorphisms that increase
the level of a-synuclein and in patients with heterozygous muta-
tion in parkin, PINK1, or DJ-1. Some transgenic a-synuclein mice
and PINK1 or DJ-1 deficient mice DA neurons are more suscep-
tible to the toxic effects of the DA neurotoxin, MPTP (Haque
et al., 2008; Kim et al., 2005; Song et al., 2004). Interestingly, par-
kin knockouts are equally sensitive compared to littermate
controls to MPTP (Thomas et al., 2007). Exploration of different
PD-associated environmental stressors in the different genetic
PD mouse models could provide insight into the interrelationship
of genetics and environmental stressors and provide models
with degeneration of DA neurons.
Arguments have been made that perhaps the reason DA
neurons don’t degenerate in the various vertebrate models is
that there are compensatory mechanisms that prevent the loss
of DA neurons during the lifespan of the mouse. Some investiga-
tors have conceptual problems with the compensation idea. The
argument is raised, why don’t humans have the same compen-
satory processes? Compensation in PD is a well-recognized
phenomenon, as well as in most neurodegenerative disorders
(for review see Bezard et al., 2003; Palop et al., 2006). Indeed,
the symptoms of PD in humans only manifest after there is
substantial degeneration of DA neurons (Bezard et al., 2003).
Both DA- and non-DA-mediated mechanisms are thought to
contribute to the substantiative presymptomatic phase of PD.
Perhaps one of the reasons that PD is a late adult neurodegen-
erative disorder is that compensatory mechanisms are active,
and it is the ultimate failure of these compensatory mechanisms
that eventually leads to neurodegeneration and the signs and
symptoms of PD. Compensation does seem to occur in mouse
models of PD. For instance, glutathione levels are increased in
parkin knockouts (Itier et al., 2003), and mitochondrial gluta-
thione peroxidase is increased in DJ-1 knockouts (Andres-
Mateos et al., 2007), and there are substantial gene expression
profile changes in a-synuclein transgenic mice. Adaptive protec-
tion is likely to begin at conception with induction of protective
genes and genes with redundant function. Identifying, under-
standing, and potentially harnessing these compensatory mech-
anisms is important, as they may provide potential biomarkers
and novel therapeutic opportunities (Palop et al., 2006).
Bypassing compensatory mechanisms by conditional overex-
pression or conditional knockout might provide an opportunity to
create models of PD where degeneration of DA neurons occurs
in the lifespan of a mouse (Figure 3). Since the mouse only lives
up to 2 years and it takes six to seven decades to develop PD,
strategies that accelerate the phenotype are required. As
mentioned above, simple overexpression of a-synuclein via
viruses is capable of eliciting neurodegeneration of DA neurons
(Kirik et al., 2003; Lo Bianco et al., 2002). Although viral-induced
overexpression of a-synuclein may induce both cell-autono-
mous and non-cell-autonomous processes, bypassing compen-
satory mechanisms needs to be considered as well. Almost all
transgenic approaches utilized to date drive expression early in
development, and all knockouts are germline deletions; thus, it
is conceivable that the DA system compensates when genes
are overexpressed or knocked out embryonically, rendering
DA neurons resistant to the toxic effects of overexpression of
a-synuclein or LRRK2 or the absence of parkin, PINK1, or DJ-1
Figure 3. Current and Future Experimental
PD Mouse Models
(A) Both mutant a-synuclein and mutant LRRK2
transgenic mice do not have loss of DA neurons.
One possible explanation is that the transgenes
are expressed early in development, leading to
compensatory mechanisms that prevent degener-
ation of DA neurons. In a similar manner, parkin,
PINK1, and DJ-1 are knocked out in the germline,
and there may be compensatory mechanisms that
also prevent degeneration of DA neurons and
provide an environment that promotes DA
neuronal survival (see text).
(B) Strategies to potentially circumvent the
compensatory mechanisms that possibly account
for the survival of DA neurons in both the auto-
somal-dominant and autosomal-recessive
models. For the autosomal-dominant models,
LRRK2 and a-synuclein transgenic mice under
the transcriptional control of the tetracycline oper-
ator (tetO) could be bred to different tetracycline
transactivator (tTA) mice to drive expression in
different neuronal populations and/or glia. Expres-
sion could be turned on in adults to avoid develop-
mental compensation. For autosomal-recessive
models, parkin, PINK1, or DJ-1, Cre-Lox recombi-
nation could be used to avoid developmental
compensation, which may mask the true patho-
physiologic action of parkin, PINK1, or DJ-1. Ad-
eno-associated virus (AAV) or lentivirus could be
used to deliver Cre in adulthood and to specific
neuronal populations and tamoxifen-sensitive
Cre mice could drive expression in different
neuronal populations and/or glia. Expression
could be turned on in adults to avoid develop-
mental compensation.
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system in neonates versus adults is differentially vulnerable to
the toxic effects of the neurotoxin 6-hydroxydopamine (6-OHDA)
(for review see Joyce et al., 1996). In adult rats, 6-OHDA causes
profound abnormalities, including sensory neglect, aphagia,
akinesia, and adipsia, whereas 6-OHDA lesions in neonates
induce minimal behavioral deficits. Thus, DA denervation in
neonates produces long-lasting modifications in the DA system.
Similar or related mechanisms accounting for this well-known
differential sensitivity of the neonatal versus the adult DA system
might account for resistance of DA neurons to toxic effects of PD
mutations.
The case for developmental plasticity of the DA system is
further illustrated through generation of glial-cell-line-derived
neurotrophic factor (GDNF) knockout mice (Pascual et al.,
2008). Embryonic deletion of GDNF and its receptors has no
effect on DA neurons during development or in the adult (Jain
et al., 2006; Moore et al., 1996). Suppressing GDNF expression
in adulthood via a conditional approach using a tamoxifen (TMX)
sensitive Cre-Lox recombination, hence avoiding develop-
mental compensation, ‘‘which masks the true physiologic action
of GDNF,’’ leads to profound degeneration of catecholamin-
ergic neurons (Pascual et al., 2008). In a similar manner, trans-
genic or knockout strategies focused on turning on transgene
expression or knocking out genes in adults might avoid the
developmental compensation and be very revealing (Figure 3).Due to the success of the adult conditional knockout of
GDNF and the ‘‘plasticity’’ of the nigrostriatal DA system, we
believe that the investment in conditional approaches that
enable deletion or expression in adult animals will have a high
probability of success and will be very rewarding. Different
TMX-sensitive Cre drivers could be used to knock out parkin,
PINK1, or DJ-1 in different neuronal populations and/or glia in
adult animals, thus avoiding developmental compensation. In
a similar manner, LRRK2 and a-synuclein transgenic mice
under the transcriptional control of the tetracycline operator
(tetO) could be bred to different tetracycline transactivator
(tTA) mice to drive expression in different neuronal populations
and/or glia. Expression could be turned on in adults to avoid
developmental compensation. If these models are successful
as defined by progressive degeneration of DA neurons, ques-
tions regarding selective vulnerability and cell-autonomous
and non-cell-autonomous mechanisms as well as the role of
molecular mechanisms of compensation could begin to be
answered by direct comparison between the different models.
Moreover, non-DA systems that are impaired in PD could be
targeted and effectively studied.
Conclusions
Although we argue above that we believe it is important to
develop models with loss of DA neurons, the field has been
somewhat hindered by the notion that any useful model shouldNeuron 66, June 10, 2010 ª2010 Elsevier Inc. 655
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it may be difficult to fully recapitulate the key neuropathologic
and clinical features of PD in a single model system, but collec-
tively many of the existing models do exhibit key features of PD.
Thus, combinatorial study of these different models may provide
insight into PD pathogenesis.
The rodent 6-OHDA and the non-human primate MPTP intox-
ication models are currently the models of choice for symptom-
atic therapies since they have been quite predictive. Their utility
as preclinical models for neuroprotection and regeneration has
been uniformly negative, although there are clinical trials
currently in progress that may change this point of view. Due
to their clinically proven predictive value for symptomatic thera-
pies, the rodent 6-OHDA and the non-human primate MPTP
intoxication models will probably remain the models of choice
for symptomatic therapies even when we have robust genetic
models with degeneration of the nigrostriatal DA system.
The study of current parkin, PINK1, and DJ-1 knockouts may
be useful to understanding the earliest abnormalities in the ni-
grostriatal DA system that occur due to these mutations. They
might also be particularly useful for understanding the molecular
mechanisms underlying compensation. In a similar manner,
current LRRK2 transgenic models may be most useful for
studying early derangements in the nigrostriatal DA system.
Some transgenic a-synuclein animal models also have progres-
sive sensorimotor anomalies that are due to dopaminergic
dysfunction (Chesselet et al., 2008). Thus, many of the models
are most useful for understanding processes that precede
degeneration. For instance, reduction of neurotransmitter
release by inhibition of synaptic vesicle reclustering after endo-
cytosis may be the earliest effect of increased a-synuclein
expression in PD and in transgenic a-synuclein models (Nemani
et al., 2010). Understanding these early processes may serve as
biomarkers or targets for therapeutic intervention.
Unfortunately, none of the existing vertebrate models are
particularly useful for investigating the mechanisms of selective
neuronal vulnerability, but as noted above, conditional
approaches, if successful, could be particularly revealing. The
Drosophila and C. elegans models that have degeneration of
DA neurons have not been used to understand selective
neuronal vulnerability. They have also failed to provide extensive
phenotypic information about affected dopaminergic neurons,
and there has been poor characterization of the effects in nondo-
paminergic neurons. Moreover, these models have not been
used to study cell-autonomous versus non-cell-autonomous
neurodegeneration. The mouse a-synuclein transgenic models
with degeneration are valuable tools to study general toxicity
and mechanisms of a-synuclein pathology as well as testing
therapeutic strategies. Unfortunately, there has been only
a paucity of neuroprotection trials in the a-synuclein mice, which
is difficult to understand. These studies confirm that maintaining
or converting a-synuclein into its monomeric state and
enhancing its degradation are therapeutic (for review see Gupta
et al., 2008). The majority of the a-synuclein transgenic models
are also useful for understanding mechanisms of degeneration
in non-DA systems. The Drosophila and C. elegans models are
teaching us about the pathogenesis of DA neurodegeneration
in flies and worms, respectively. The challenge remains to vali-656 Neuron 66, June 10, 2010 ª2010 Elsevier Inc.date potential neuroprotective agents and genetic modifiers
identified in these model systems in human PD.
Only a few studies have focused on assays to study non-DA
systems that are affected in PD. However, due to the relative
lack of alterations in the nigrostriatal system, studies should be
focused on non-DA neuronal dysfunction. Expanding the reper-
toire of investigations in PD models might be particularly
revealing. For instance, some of the earliest changes in PD are
olfactory dysfunction, sleep disturbances, and cardiac sympa-
thetic denervation (Langston, 2006). PD patients also suffer
from constipation, anxiety, depression, and cognitive impair-
ments. Thus, tests of olfaction, sleep monitoring, behavioral
assessments focused on anxiety, depression, and memory,
and assessing autonomic function in the existing different
models would be important. The study of these nonmotor mani-
festations in animal models might be rewarding, particularly if
disturbances manifest early in the life of a mouse and if they
were progressive. Some of the a-synuclein transgenic mice
have olfactory impairments and colonic dysfunction, and it is
likely that there are other unrecognized abnormalities (Fleming
et al., 2008; Wang et al., 2008b). Understanding and study of
potential abnormalities in these nonmotor systems could offer
new models for testing neuroprotective agents as well as provide
new models for testing symptomatic therapies focused on the
nonmotor manifestations of PD.
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